Iterum Therapeutics PLCNASDAQ:ITRMNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.2500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.2500/ 131
- Ask / Lots1.2900/ 4
- Open / Previous Close1.2500 / 1.2500
- Day Range
- 52 Week Range
- Volume297,443
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ITRM |
|---|---|---|
| 09:32 ET | 426 | 1.25 |
| 09:34 ET | 100 | 1.25 |
| 09:38 ET | 2906 | 1.27 |
| 09:41 ET | 41257 | 1.27 |
| 09:50 ET | 500 | 1.26 |
| 09:52 ET | 2115 | 1.26 |
| 09:54 ET | 100 | 1.26 |
| 09:59 ET | 15256 | 1.28 |
| 10:01 ET | 5100 | 1.275 |
| 10:03 ET | 4099 | 1.29 |
| 10:06 ET | 1200 | 1.28 |
| 10:15 ET | 238 | 1.26 |
| 10:19 ET | 200 | 1.26 |
| 10:24 ET | 750 | 1.2546 |
| 10:32 ET | 600 | 1.27 |
| 10:37 ET | 100 | 1.27 |
| 10:42 ET | 1100 | 1.2595 |
| 10:51 ET | 980 | 1.24 |
| 10:53 ET | 1000 | 1.2435 |
| 11:02 ET | 2725 | 1.23 |
| 11:04 ET | 1000 | 1.23 |
| 11:06 ET | 4000 | 1.23 |
| 11:09 ET | 3300 | 1.2397 |
| 11:13 ET | 1400 | 1.24 |
| 11:31 ET | 133 | 1.24 |
| 11:40 ET | 466 | 1.245 |
| 11:42 ET | 300 | 1.24 |
| 11:44 ET | 1000 | 1.25 |
| 12:00 ET | 200 | 1.24 |
| 12:03 ET | 100 | 1.2497 |
| 12:09 ET | 700 | 1.24 |
| 12:16 ET | 733 | 1.235 |
| 12:30 ET | 905 | 1.24 |
| 12:32 ET | 1040 | 1.24 |
| 12:34 ET | 8209 | 1.23 |
| 12:38 ET | 271 | 1.2299 |
| 12:41 ET | 2018 | 1.22 |
| 12:43 ET | 1000 | 1.2185 |
| 12:45 ET | 2355 | 1.22 |
| 12:50 ET | 1500 | 1.225 |
| 12:52 ET | 4158 | 1.23 |
| 12:54 ET | 1187 | 1.24 |
| 12:56 ET | 100 | 1.24 |
| 01:03 ET | 3824 | 1.234 |
| 01:06 ET | 724 | 1.24 |
| 01:17 ET | 3970 | 1.24 |
| 01:24 ET | 12498 | 1.25 |
| 01:26 ET | 8970 | 1.25 |
| 01:30 ET | 5947 | 1.25 |
| 01:32 ET | 20634 | 1.25 |
| 01:33 ET | 1606 | 1.265 |
| 01:44 ET | 7574 | 1.27 |
| 01:48 ET | 1378 | 1.2693 |
| 01:50 ET | 1600 | 1.2675 |
| 01:51 ET | 10203 | 1.26 |
| 01:53 ET | 10200 | 1.26 |
| 01:55 ET | 10111 | 1.25 |
| 02:09 ET | 133 | 1.257 |
| 02:11 ET | 600 | 1.25 |
| 02:31 ET | 600 | 1.25 |
| 02:36 ET | 300 | 1.25 |
| 02:38 ET | 300 | 1.25 |
| 02:40 ET | 300 | 1.25 |
| 02:45 ET | 1300 | 1.25 |
| 02:47 ET | 600 | 1.25 |
| 02:49 ET | 200 | 1.25 |
| 02:51 ET | 100 | 1.25 |
| 02:54 ET | 900 | 1.26 |
| 02:56 ET | 530 | 1.25 |
| 02:58 ET | 3901 | 1.255 |
| 03:00 ET | 200 | 1.24 |
| 03:02 ET | 693 | 1.245 |
| 03:03 ET | 200 | 1.23 |
| 03:05 ET | 200 | 1.23 |
| 03:07 ET | 5200 | 1.25 |
| 03:12 ET | 200 | 1.24 |
| 03:14 ET | 5713 | 1.25 |
| 03:20 ET | 1100 | 1.24 |
| 03:21 ET | 200 | 1.24 |
| 03:23 ET | 200 | 1.24 |
| 03:25 ET | 400 | 1.24 |
| 03:27 ET | 25200 | 1.25 |
| 03:30 ET | 4576 | 1.25 |
| 03:34 ET | 200 | 1.25 |
| 03:36 ET | 200 | 1.25 |
| 03:38 ET | 700 | 1.25 |
| 03:39 ET | 500 | 1.25 |
| 03:41 ET | 400 | 1.25 |
| 03:43 ET | 400 | 1.25 |
| 03:45 ET | 200 | 1.25 |
| 03:48 ET | 1890 | 1.25 |
| 03:50 ET | 2315 | 1.25 |
| 03:52 ET | 1250 | 1.25 |
| 03:54 ET | 800 | 1.25 |
| 03:56 ET | 1900 | 1.25 |
| 03:57 ET | 2200 | 1.25 |
| 03:59 ET | 2600 | 1.25 |
Jul 22, 2024
Iterum Therapeutics Commences Rights Offering, from 7:30AM ET on Monday Jul 22, 2024 by Dow Jones
7:30AM ET on Monday Jul 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Iterum Therapeutics PLC | 20.7M | -0.5x | --- |
Forte Biosciences Inc | 20.8M | -0.5x | --- |
Carmell Corp | 20.6M | -0.6x | --- |
Bioxytran Inc | 21.0M | -4.0x | --- |
Goldenwell Biotech Inc | 19.8M | -168.1x | --- |
Minerva Neurosciences Inc | 21.8M | -0.7x | --- |
Company Information
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.
Contact Information
- Headquarters
- Fitzwilliam Court 1st Floor, Leeson Close, Dublin 2DUBLIN, Ireland D02 YW24
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the board
- Brenton Ahrens
- President, Chief Executive Officer, Director
- Corey Fishman
- Chief Financial Officer
- Judith Matthews
- Director
- Michael Dunne
- Independent Director
- Beth Hecht
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $20.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 16.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.23 |
EPS | $-2.64 |
Book Value | $-0.47 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
